Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Yueyin Pan's publication output changed over time?
ScholarIQpublication output · 2019–2023
Output grew300% over the shown period — from 1 works in 2019 to 4 in 2023.
1
3
1
2
4
20192020202120222023
What are the most-cited papers on Yueyin Pan?
ScholarIQmost cited works
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz‐Josef Klümpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel, Arndt Vogel, Mehmet Akce, Inmaculada Alés Díaz, Gustavo R. Alves, Sumitra Anand, Çağatay Arslan, Jamil Asselah, Eric Assenat, F. Aubin, Li‐Yuan Bai, Yuxian Bai, Olga Barajas, Susan E. Bates, Stephen Begbie, Irit Ben‐Aharon, Nina Beri, Marie‐Luise Berres, Jean‐Frédéric Blanc, Ivan Borbath, Robert Bordonaro, Mohamed Bouattour, Giovanni Brandi, Adam M. Burgoyne, Kritiya Butthongkomvong, Marcos Pedro Guedes Camandaroba, Ke Cao, Marcela Carballido, Jen‐Shi Chen, Jen‐Shi Chen, Ming-Huang Chen, Ashley Cheng, Ashley Cheng, Tai‐Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joëlle Collignon, Antonio Cubillo Gracián, S. Lindsey Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith de Vos, Maria Diab, Jacob C. Easaw, Martin Eatock, Julien Edeline, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernández, Richard Finn, Fábio Franke, Masayuki Furukawa, Junji Furuse, Olumide B. Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Oliver Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gümüş, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoğlu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Jun‐Eul Hwang, Mevlüde İnanç, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jiménez Fonseca, Warren Joubert
The Lancet. 20231,086 CitationsOPEN ACCESS
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang, Jianming Xu, Yun Chen, Wu Zhuang, Yiping Zhang, Zhendong Chen, Jia Chen, Helong Zhang, Zuoxing Niu, Qingxia Fan, Lizhu Lin, Kangsheng Gu, Ying Liu, Yi Ba, Zhanhui Miao, Xiaodong Jiang, Ming Zeng, Jianhua Chen, Zhichao Fu, Lu Gan, Jun Wang, Xianbao Zhan, Tianshu Liu, Zhiping Li, Lin Shen, Yongqian Shu, Tao Zhang, Qing Yang, Jianjun Zou, Suxia Luo, Feng Peng, Gang Wu, Nong Xu, Lin Zhao, Dong Ma, Shukui Qin, Wei Ren, Enxiao Li, Hongda Lu, Yueyin Pan, Jianping Xiong, Ying Yuan, Yuxian Bai, Lei Chen, Yi Hu, Li Zhang, Yong Gao
The Lancet Oncology. 2020591 Citations
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Fengying Wu, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, Liping Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, Xiaorong Dong, Tao Zhang, Wei Shi, Jianjun Zou
The Lancet Respiratory Medicine. 2020508 Citations
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
Zhihao Lü, Junye Wang, Yongqian Shu, Lianke Liu, Li Ren Kong, Lei Yang, Buhai Wang, Guogui Sun, Yinghua Ji, Guochun Cao, Hu Liu, Tongjian Cui, Na Li, Wensheng Qiu, Gaofeng Li, Xinfang Hou, Hui Luo, Liying Xue, Yanqiao Zhang, Wenbin Yue, Zheng Liu, Xiuwen Wang, Shegan Gao, Yueyin Pan, Marie‐Pierre Galais, Aziz Zaanan, Zhuo Ma, Haoyu Li, Yan Wang, Lin Shen
BMJ. 2022493 CitationsOPEN ACCESS
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
Ying Cheng, Liang Han, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Mikhail Dvorkin, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Wenying Kang, Qingyu Wang, Jun Zhu, ASTRUM-005 Study Group, Xiubao Ren, Vladimer Kuchava, Guoping Sun, Gaofeng Li, Lin Wen, Tao Zhang, Hakan Harputluoğlu, İrfan Çiçin, Guosheng Feng, Yanrong Hao, Kejing Ying, Ping Sun, Aihong Zhong, Guangyu An, Yan Wang, Chun Chen, Sheng Yang, Zhendong Chen, Konstantin Penkov, Yuriy Semegen, Oleg Kobziev, Feng Luo, Peiguo Cao, Zhixiong Yang, Min Fan, Wen Li, Robert Mróz, А. Л. Акопов, Tuncay Göksel, Mahmut Gümüş, Wenlei Zhuo, Jian Fang, Hui Zhao, Lin Zhong, Yanping Hu, Yarong Li, Shuqun Zhang, Jiuwei Cui, Н. В. Коваленко, Çağatay Arslan, Devrim Cabuk, Alev Türker, Igor Bondarenko, Yevhen Hotko, O. Goloborodko, Dongji Chen, Mengzhao Wang, Zhuang Yu, Jun‐Guo Lu, Liyan Jiang, Hao Xiong, Davit Giorgadze, Sergey Orlov, Ahmet Bılıcı, Ivan Sinelnikov, Gongyan Chen, Yue Lu, Xiaoli Zhu, Liqin Lu, Mariam Zhvania, Małgorzata Ułańska, Igor Lifirenko, Timur Andabekov, Maria Smagina, Fedor Moiseenko, Yüksel Ürün, Ligong Nie, Bangwei Cao, Zhenyu You, Haixin Huang, Shenpeng Ying, Alexandre Tavartkiladze, Tariel Kitiashvili, Amiran Matitashvili
JAMA. 2022469 CitationsOPEN ACCESS
Related on ScholarIQ
University of Science and Technology of China
Institution
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Paper
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Paper
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Paper
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
Paper
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
Paper